about
B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric diseaseB-Raf and the inhibitors: from bench to bedsideMain roads to melanomaMelanoma: from melanocyte to genetic alterations and clinical optionsRaf family kinases: old dogs have learned new tricksBrn-2 expression controls melanoma proliferation and is directly regulated by beta-cateninTWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cellsClinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaThe Brn-2 transcription factor links activated BRAF to melanoma proliferationAnalysis of the genome to personalize therapy for melanomaExome sequencing identifies recurrent somatic RAC1 mutations in melanomaThe histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onsetMutations in GNA11 in uveal melanomaIn vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanomaFOXD3 regulates migration properties and Rnd3 expression in melanoma cellsFrequent somatic mutations of GNAQ in uveal melanoma and blue naeviDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityOncogenic mutations in GNAQ occur early in uveal melanomaMitf regulation of Dia1 controls melanoma proliferation and invasivenessConstitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosisB-Raf specific antibody responses in melanoma patientsClinical significance of BRAF mutations in metastatic melanomaTowards a Better Understanding of the Molecular Mechanisms Involved in Sunlight-Induced MelanomaPreponderance of the oncogenic V599E and V599K mutations in B-raf kinase domain is enhanced in melanoma cutaneous/subcutaneous metastasesRecent advances in molecular genetics of melanoma progression: implications for diagnosis and treatmentThe Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin CancerUveal Melanoma Patient-Derived XenograftsUpdates in Therapy for Advanced MelanomaCurrent State of Animal (Mouse) Modeling in Melanoma ResearchMultiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic TargetsPathways and therapeutic targets in melanomaInvestigative pathology: leading the post-genomic revolutionTargeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancersEmerging phytochemicals for prevention of melanoma invasionMelanoma: from mutations to medicineReconstructing skin cancers using animal modelsTargeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondPyrazolopyridine Inhibitors of B-Raf V600E . Part 1: The Development of Selective, Orally Bioavailable, and Efficacious InhibitorsElucidating distinct roles for NF1 in melanomagenesisNRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.
P2860
Q21134717-9CCD6541-8447-43C8-94AC-8B03A75E1CD9Q21198860-28D9A35F-6667-4D35-97ED-42156C313531Q21245465-29DE2180-CDD0-4636-B18D-14A6658A22E4Q21284811-E2352031-AF88-4D3C-8EF2-1494D30561F0Q24316181-6B81748C-1C7A-4DCA-A1A0-C26933129891Q24317170-96229DC1-F323-4AAE-9F2F-83A468B0DAE2Q24594566-05E5D8D5-2E1C-40CD-A816-9ADDCA3CBF9AQ24597152-6C63BD92-0DE8-473F-9D65-B7C739E904F4Q24599712-67731D53-6A76-40C8-95F3-D2673E40BCA5Q24601008-C8F41435-F693-41EF-882E-BE640A6574BAQ24607661-22BBBE17-1D92-4625-A759-2030538DD517Q24625220-656EA83A-3C5C-45F9-8CB2-A6FD652F7311Q24625723-ECAC8D05-5386-44AA-A013-6E629064C577Q24629400-29EFA02D-922A-44C8-A27A-E059166BCFD1Q24633339-4B6EB545-98FA-44D6-9F5B-65DE463F1860Q24646052-0978C037-6711-4638-AB33-886EA60388FCQ24652600-05E41E84-0E11-490D-92E3-840057743B01Q24658558-D07DC556-F1AC-4B46-B5DB-9CD7E8113879Q24672631-9763D09F-4C97-4209-B0CB-2E291F3922A3Q24791830-23716206-3365-4696-BC35-881D2BE9450AQ24794587-08C6BE0D-231C-4FE4-B133-4AD76D4439E3Q24803115-2BC37CEE-31F2-4A3D-9AAF-2B86A9FF4CCEQ24806589-52F83432-7923-4E20-AC10-746EDA7375F0Q24814098-3CA421B4-009F-4B2C-BA45-BA28378A19F7Q26740631-FF537D65-60BB-45C6-8C0B-185583796B5AQ26747247-A234C824-9CD7-4E4D-9B66-DB8495603D87Q26750371-9EC9F605-A6A5-4219-823D-E21B0EA2377DQ26771119-5AE0F2CF-BFA5-46A6-8C92-953923289F27Q26781652-224CCFC0-13ED-4FAD-BDEB-4E8DA42A4C9DQ26795735-E7679D40-41F6-49B6-888D-6B3E61FDB095Q26865736-398EA695-9A8D-4830-9B32-B0EB5DA29D01Q27002945-DC8DDB3C-08AC-40E6-923E-75C986877BFEQ27022240-E8BE738B-3261-4071-B515-AD8F4CB10671Q27023283-CCF5EE8A-BC35-45CD-AE92-0CBD2EB475CFQ27024061-475293D3-4A04-44AF-9873-B042053A1EA4Q27024320-A5CCA017-CB49-437B-BA16-50CC29E9EEE8Q27026323-4033D025-EA72-41F3-9CAF-5FD158F36FABQ27684109-037D58C2-CC11-46A1-BE90-E29ECB415379Q27851952-3BB517FE-5C52-4A1E-9688-E39A18A1FE98Q27852445-C45CBDCF-B502-4D2C-BEE9-2CD7FE57E1DE
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
High frequency of BRAF mutations in nevi.
@ast
High frequency of BRAF mutations in nevi.
@en
High frequency of BRAF mutations in nevi.
@nl
type
label
High frequency of BRAF mutations in nevi.
@ast
High frequency of BRAF mutations in nevi.
@en
High frequency of BRAF mutations in nevi.
@nl
prefLabel
High frequency of BRAF mutations in nevi.
@ast
High frequency of BRAF mutations in nevi.
@en
High frequency of BRAF mutations in nevi.
@nl
P2093
P2860
P50
P356
P1433
P1476
High frequency of BRAF mutations in nevi.
@en
P2093
Christiane M Robbins
Galen Hostetter
Ghadi Salem
Jeffrey M Trent
Katherine S Hansen
Laura M Yudt
Nicholas K Hayward
Paul Duray
Paul S Meltzer
Peter Heenan
P2860
P2888
P356
10.1038/NG1054
P407
P577
2002-11-25T00:00:00Z